Listen Now

In this podcast, expert clinicians discuss the latest updates on anti-integrin therapy and S1P receptor modulators in IBD management.

In this podcast, expert clinicians discuss the latest updates on JAK inhibition in IBD management.

In this podcast, expert clinicians discuss the latest updates on anti-IL-12/23 therapy in IBD management.

In this podcast, expert clinicians discuss the latest updates on anti-TNF therapy in IBD management.

In this podcast, expert clinicians compare the immunogenicity of available biologic therapies and explore options for managing patients who develop anti-drug antibodies. 

In this podcast, expert clinicians review the variety of extraintestinal manifestations seen in patients with IBD, discussing strategies for assessment and management.

In this podcast, experts review appropriate applications of monotherapy and combination therapy and how to position particular therapies based on disease and patient characteristics. 

In this podcast, expert clinicians will discuss the shift from symptom-based management to a treat-to-target paradigm, detailing important treatment aims and reviewing the mechanisms of action of available therapies. 

In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-IL-23 and JAK inhibitors, that are in late-stage development for treating moderate to severe CD.

In this podcast, expert clinicians will discuss new evidence on investigational agents, the anti-integrin and S1P-1 receptor modulators, that are in late-stage development for treating moderate to severe CD.

In this podcast, expert clinicians will discuss emerging therapies with unique mechanisms of action that can improve the treatment of moderate to severe Crohn’s disease.

Investigational Agents in Ulcerative Colitis: IL-12 and IL-23 InhibitorsInflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. Peter Higgins and Dr. David Rubin will discuss investigational interleukin-12 and interleukin-23 inhibitors for treating UC. For the transcript of this podcast, click here. To obtain CME credit, click here

Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. Peter Higgins and Dr. William Sandborn will discuss investigational Janus kinase inhibitors and sphingosine-1-phosphate receptor modulators for treating UC. For the transcript of this podcast, click here. To obtain CME credit, click here

Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, Dr. David Rubin and Dr. Peter Higgins will discuss investigational anti-integrin therapies for UC. For the transcript of this podcast, click here To obtain CME credit, click here

Inflammatory bowel disease, which includes ulcerative colitis (UC) and Crohn’s disease, affects an estimated 3 million adults in the United States. Although numerous therapies are available for the treatment of moderate to severe UC, many patients still suffer poor quality of life and suboptimal outcomes. Therefore, safer and more effective UC therapies are needed. In this CME podcast activity, expert physicians will discuss investigational UC therapies with various mechanisms of action. For the full CME activity, click here